Update on the Adoption And Utilization of Emerging Precision Medicine Biomarkers and Technologies in Routine Clinical Care
At DeciBio Consulting, our mission is to provide market intelligence and insights to advance precision medicine. To this end, we track this space closely, especially the field of precision oncology,
DeciBio’s Q&A with Brady Davis, SVP of Business Development for Canexia Health
DeciBio had the pleasure of interviewing Canexia Health’s SVP of Business Development, Brady Davis. We interviewed Brady to understand how Canexia Health and Project ACTT (Access to Testing and
While Apple & Google’s technology holds promise over traditional contact tracing and other, less privacy-friendly methods of digital surveillance being used across the globe, perceived data privacy and security
Cancer Immunotherapy Biomarker Spotlight: Immune Function Markers / Analyses
We’ve been tracking the cancer immunotherapy biomarker space closely via our Immuno-Oncology BioMAP for years and have witnessed the rapid growth and evolution of immuno-oncology first hand. The amount of
A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers
We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light
Los Angeles, CA March 2, 2020 – This morning, Quantum Si introduced a potentially highly disruptive instrument, an equivalent to NGS for high-throughput protein sequencing. The company is part of
Evolution in the precision oncology landscape – Part 2 (Therapeutic Developments)
Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.
Oncology Cell Therapy Companies Race to the Finish Line
Tracking the Oncology Cell Therapy Space Cell therapies is a rapidly growing space with huge potential to improve oncology patient outcomes. As examples, the two approved CAR-T products Yescarta (Kite/Gilead)
In mid-November, speculation began that ThermoFisher was in talks with QIAGEN surrounding a potential acquisition. A hypothetical tie-up could help Thermo bolster its reach into clinical diagnostic tests and nucleic